Discovery of New Antifungal Leads via Pharmacophore Modeling and QSAR Analysis of Fungal N-Myristoyl Transferase Inhibitors Followed by In Silico Screening

Chemical Biology and Drug Design

Volumn 78, Issue 3, 2011, Pages 391-407

  Taha, Mutasem O ^a   Qandil, Amjad M ^b   Al Haraznah, Tariq ^c   Khalaf, Reema Abu ^b   Zalloum, Hiba ^a   Al Bakri, Amal G ^a  

^a UNIVERSITY OF JORDAN   (Jordan)

^b JORDAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Jordan)

^c AL ZAYTOONAH UNIVERSITY OF JORDAN   (Jordan)

Author keywords

In silico screening; NMT; Pharmacophore modeling; QSAR; ROC curves

Indexed keywords

ANTIFUNGAL AGENT; CARVEDILOL; NSC 102844; NSC 109836; NSC 116491; NSC 121428; NSC 12503; NSC 130815; NSC 14071; NSC 153423; NSC 15792; NSC 222808; NSC 23677; NSC 261408; NSC 314594; NSC 32929; NSC 330722; NSC 33112; NSC 342912; NSC 354676; NSC 370864; NSC 375390; NSC 62323; NSC 656354; PROTEIN N MYRISTOYLTRANSFERASE INHIBITOR; THIORIDAZINE; UNCLASSIFIED DRUG;

ARTICLE; COMPUTER MODEL; DATA MINING; DRUG BINDING SITE; DRUG CONFORMATION; DRUG SCREENING; DRUG STRUCTURE; MOLECULAR MODEL; PHARMACOPHORE; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

ACYLTRANSFERASES; ANTIFUNGAL AGENTS; DRUG DESIGN; ENZYME INHIBITORS; FUNGI; HUMANS; LIGANDS; MODELS, MOLECULAR; MYCOSES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 80051589872     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2011.01160.x     Document Type: Article

References (73)

1. Fridkin S., Jarvis W. (1996) Epidemiology of nosocomial fungal infections. Clin Microbiol Rev;9:499-511.
2. Kawasaki K., Masubuchi M., Ebiike H., Morikami K., Hayase M., Shindoh H., Sogabe S., Fujii T., Sakata K., Shiratori Y., Aoki Y., Ohtusuka T., Shimma N., Aoyama T., Niizuma S. (2003) Design and synthesis of novel benzofurans as a new class of antifungal agents targeting fungal N-myristoyltransferase. Part 3. Bioorg Med Chem Lett;13:87-91.
3. Devadas B., Freeman S.K., Zupec M.E., Lu H., Nagarajan S.R., Kishore N., Lodge J., Kuneman D., McWherter C., Vinjamoori D., Getman D., Gordon J., Sikorski J. (1997) Design and synthesis of novel imidazole-substituted dipeptide amides as potent and selective inhibitors of Candida albicans myristoylCoA:protein N-myristoyltransferase and identification of a related tripeptide inhibitor with mechanism-based antifungal activity. J Med Chem;40:2609-2625.
4. Mcwherter C., Rocque W., Wood D., Gordon J. (1993) A comparative analysis of the kinetic mechanism and peptide substrate specificity of human and Saccharomyces cerevisiae myristoyl-CoA:protein N-myristoyltransferase. J Biol Chem;268:9964-9971.
5. Farazi T., Waksman G., Gordon J. (2001) The biology and enzymology of protein N-myristoylation. J Biol Chem;276:39501-39504.
6. Gordon J., Duronio R., Rudnick D., Adams S., Gokel G. (1991) Protein N-myristoylation. J Biol Chem;266:8647-8650.
7. Peitzsch M., McLaughlin S. (1993) Binding of acylated peptides and fatty acids to phospholipid vesicles: pertinence to myristoylated proteins. Biochemistry;32:10436-10443.
8. Wilcox C., Hu J., Olson E. (1987) Acylation of proteins with myristic acid occurs cotranslationally. Science;238:1275-1278.
9. Freeman S., McWherter C., Gordon J., Wood D., Weinberg R., Lee S. (1995) Genetic studies reveal that myristoylCoA:protein N-myristoyltransferase is an essential enzyme in Candida albicans. Mol Microbiol;16:241-250.
10. Lodge J., Jackson-Machelski E., Toffaletti D., Perfect J., Gordon J. (1994) Targeted gene replacement demonstrates that myristoyl-CoA:protein N-myristoyltransferase is essential for viability of Cryptococcus neoformans. Proc Natl Acad Sci U S A;91:12008-12012.
11. Nakayama H., Mio T., Nagahashi S., Kokado M., Arisawa M., Aoki Y. (2000) Tetracycline-regulatable system to tightly control gene expression in the pathogenic fungus Candida albicans. Infect Immun;68:6712-6719.
12. Masubuchi M., Sogabe S., Sakata K., Fukami T., Morikami K., Shiratori Y., Ebiike H., Kawasaki K., Aoki Y., Shimma N., Allan D., Winkler F., Banner D., Tatsuo O. (2002) Crystal structures of Candida albicans N-myristoyltransferase with two distinct inhibitors. Chem Biol;9:1119-1128.
13. Devadas B., Freeman S., McWherter C., Kishore N., Lodge J., Jackson-Machelski E., Gordon J., Sikorski J. (1998) Novel biologically active nonpeptidic inhibitors of myristoylCoA:protein N-myristoyltransferase. J Med Chem;41:996-1000.
14. Devadas B., Zupec M., Freeman S., Brown D., Nagarajan S., Sikorski J., McWherter C., Getman D., Gordon J. (1995) Design and syntheses of potent and selective dipeptide inhibitors of Candida albicans myristoyl-CoA:protein N-myristoyltransferase. J Med Chem;38:1837-1840.
15. Paige L., Zheng G., DeFrees S., Cassady J., Geahlen R. (1990) Metabolic activation of 2-substituted derivatives of myristic acid to form potent inhibitors of myristoyl CoA:protein N-myristoyltransferase. Biochemistry;29:10566-10573.
16. Parang K., Knaus E., Wiebe L., Sardari S., Daneshtalab M., Csizmadia F. (1996) Synthesis and antifungal activities of myristic acid analogs. Arch Pharm;329:475-482.
17. Karki G., Kulkarni V. (2001) A feature based pharmacophore for Candida albicans MyristoylCoA: protein N-myristoyltransferase inhibitors. Eur J Med Chem;36:147-163.
18. Masubuchi M., Kawasaki K., Ebiike H., Ikeda Y., Tsujii S., Sogabe S., Fujii T., Sakata K., Shiratori Y., Aoki Y., Ohtsuka T., Shimma N. (2001) Design and synthesis of novel benzofurans as a new class of antifungal agents targeting fungal N-myristoyltransferase. Part 1. Bioorg Med Chem Lett;11:1833-1837.
19. Masubuchi M., Ebiike H., Kawasaki K., Sogabe S., Morikami K., Shiratori Y., Tsujii S., Fujii T., Sakata K., Hayase M., Shindoh H., Aoki Y., Ohtsuka T., Shimma N. (2003) Synthesis and biological activities of benzofuran antifungal agents targeting fungal N-myristoyltransferase. Bioorg Med Chem;11:4463-4478.
20. Ebara S., Naito H., Nakazawa K., Ishii F., Nakamura M. (2005) FTR1335 is a novel synthetic inhibitor of Candida albicans N-myristoyltransferase with fungicidal activity. Biol Pharm Bull;28:591-595.
21. Telvekar V.N., Kundaikar H.S., Patel K.N., Chaudhari H.K. (2008) 3-D QSAR and molecular docking studies on aryl benzofuran-2-yl ketoxime derivatives as Candida albicans N-myristoyl transferase inhibitors. QSAR Comb Sci;27:1193-1203.
22. Wu J., Tao Y., Zhang M., Howard M.H., Gutteridge S., Ding J. (2007) Crystal structures of Saccharomyces cerevisiae N-myristoyltransferase with bound myristoyl-CoA and inhibitors reveal the functional roles of the N-terminal region. J Biol Chem;282:22185-22194.
23. Farazi T.A., Waksman G., Gordon J.I. (2001) Structures of Saccharomyces cerevisiae N-myristoyltransferase with bound myristoylCoA and peptide provide insights about substrate recognition and catalysis. Biochemistry;40:6335-6343.
24. Weston S.A., Camble R., Colls J., Rosenbrock G., Taylor I., Egerton M., Tucker A.D., Tunnicliffe A., Mistry A., Mancia F., de la Fortelle E., Irwin J., Bricogne G., Pauptit R.A. (1998) Crystal structure of the anti-fungal target N-myristoyl transferase. Nat Struct Biol;5:213-221.
25. Bhatnagar R.S., Futterer K., Farazi T.A., Korolev S., Murray C.L., Jackson-Machelski E., Gokel G.W., Gordon J.I., Waksman G. (1998) Structure of N-myristoyltransferase with bound myristoylCoA and peptide substrate analogs. Nat Struct Biol;5:1091-1097.
26. Bitencourt M., Freitas M.P. (2009) Bi- and multilinear PLS coupled to MIA-QSAR in the prediction of antifungal activities of some benzothiazole derivatives. J Med Chem;5:79-86.
27. Deokar H.S., Puranik P., Kulkarni V.M. (2009) QSAR analysis of N-myristoyltransferase inhibitors: antifungal activity of benzofurans. Med Chem Res;18:206-220.
28. Li W., Zhao X., Liu F., Hou B. (2008) Investigation on inhibition behavior of S-triazole-triazole derivatives in acidic solution. Corros Sci;50:3261-3266.
29. Zhu J., Sheng C.Q., Zhang M., Song Y.L., Chen J., Yu J.X., Yao J.Z., Miao Z.Y., Zhang W.N. (2006) 3D-QSAR study of a series of novel benzofuran NMT inhibitors. Gaodeng Xuexiao Huaxue Xuebao;27:287-291.
30. Hasegawa K., Morikami K., Shiratori Y., Ohtsuka T., Aoki Y., Shimma N. (2003) 3D-QSAR study of antifungal N-myristoyltransferase inhibitors by comparative molecular surface analysis. Chemom Intell Lab Syst;69:51-59.
31. Purushottamachar P., Kulkarni V.M. (2003) 3D-QSAR of N-myristoyltransferase inhibiting antifungal agents by CoMFA and CoMSIA methods. Bioorg Med Chem;11:3487-3497.
32. Beeley N.R.A., Sage C. (2003) GPCRs: an update on structural approaches to drug discovery. Targets;2:19-25.
33. Klebe G. (2006) Virtual ligand screening: strategies, perspectives and limitations. Drug Discov Today;11:580-594.
34. Steuber H., Zentgraf M., Gerlach C., Sotriffer C.A., Heine A., Klebe G.J. (2006) Expect the unexpected or caveat for drug designers: multiple structure determinations using aldose reductase crystals treated under varying soaking and co-crystallisation conditions. Mol Biol;363:174-187.
35. Stubbs M.T., Reyda S., Dullweber F., Moller M., Klebe G., Dorsch D., Mederski W., Wurziger H. (2002) pH-dependent binding modes observed in trypsin crystals: lessons for structure-based drug design. ChemBioChem;3:246-249.
36. DePristo M.A., de Bakker P.I.W., Blundell T.L. (2004) Heterogeneity and inaccuracy in protein structures solved by X-ray crystallography. Structure;12:831-838.
37. Akamatsu M. (2002) Current state and perspectives of 3D-QSAR. Curr Top Med Chem;12:1381-1394.
38. Taha M., Qandil A., Zaki D., AlDamen M. (2005) Ligand-based assessment of factor Xa binding site flexibility via elaborate pharmacophore exploration and genetic algorithm-based QSAR modeling. Eur J Med Chem;40:701-727.
39. Taha M.O., Bustanji Y., Al-Ghussein M., Mohammad M., Zalloum H., Al-Masri I.M., Atallah N. (2008) Pharmacophore modeling, quantitative structure-activity relationship analysis, and in silico screening reveal potent glycogen synthase kinase-3β inhibitory activities for cimetidine, hydroxychloroquine, and gemifloxacin. J Med Chem;51:2062-2077.
40. Taha M.O., Dahabiyeh L.A., Bustanji Y., Zalloum H., Saleh S. (2008) Combining ligand-based pharmacophore modeling, quantitative structure-activity relationship analysis and in silico screening for the discovery of new potent hormone sensitive lipase inhibitors. J Med Chem;51:6478-6494.
41. Taha M.O., Atallah N., Al-Bakri A.G., Paradis-Bleau C., Zalloum H., Younis K., Levesque R.C. (2008) Discovery of new MurF inhibitors via pharmacophore modeling and QSAR analysis followed by in-silico screening. Bioorg Med Chem;16:1218-1235.
42. Taha M.O., Bustanji Y., Al-Bakri A.G., Yousef M., Zalloum W.A., Al-Masri I.M., Atallah N. (2007) Discovery of new potent human protein tyrosine phosphatase inhibitors via pharmacophore and QSAR analysis followed by in silico screening. J Mol Graphics Models;25:870-884.
43. Abu Hammad A.M., Taha M.O. (2009) Pharmacophore modeling, quantitative structure-activity relationship analysis, and shape-complemented in silico screening allow access to novel influenza neuraminidase inhibitors. J Chem Inf Model;49:978-996.
44. Bersuker I.B., Bahçeci S., Boggs J.E. (2000) In: Güner O.F., editor. Pharmacophore Perception, Development, and Use in Drug Design. California: International University Line; p. 457-473.
45. Kurogi Y., Güner O. (2001) Pharmacophore modeling and three-dimensional database searching for drug design using catalyst. Curr Med Chem;8:1035-1055.
46. Accelrys Inc. (2006) Proceedings of the 9th European CATALYST User Group Meeting Advanced Seminars in CATALYST. Frankfurt, Germany. San Diego, CA: Accelrys Inc.
47. Sutter J., Güner O., Hoffmann R., Li H., Waldman M. (2000) In: Güner O.F., editor. Pharmacophore Perception, Development, and Use in Drug Design. California: International University Line; p. 501-511.
48. Sutter H., Li J., Hoffmann R., Güner O.F. (2000) In: Güner O.F., editor. Pharmacophore Perception, Development, and Use in Drug Design. California: International University Line; p. 73-189.
49. Taha M., Al-Bakri A., Zalloum W. (2006) Discovery of potent inhibitors of pseudomonal quorum sensing via pharmacophore modeling and in silico screening. Bioorg Med Chem Lett;16:5902-5906.
50. Ebiike H., Masubuchi M., Liu P., Kawasaki K., Morikami K., Sogabe S., Hayase M., Fujii T., Sakata K., Shindoh H., Shiratori Y., Aoki Y., Ohtsukaa T., Shimmaa N. (2002) Design and synthesis of novel benzofurans as a new class of antifungal agents targeting fungal N-myristoyltransferase. Part 2. Bioorg Med Chem Lett;12:607-610.
51. Smellie A., Kahn S., Teig S. (1995) Analysis of conformational coverage. 1. Validation and estimation of coverage. J Chem Inf Comput Sci;35:285-294.
52. Poptodorov K., Luu T., Hoffmann R. (2006) Methods and principles in medicinal chemistry. In: Langer T., Hoffmann R., editors. Pharmacophores and Pharmacophores Searches. Weinheim: WILEY-VCH; p. 17-47.
53. Fisher R. (1966) The Principle of Experimentation Illustrated by a Psycho-Physical Exp., 8th edn, Chapter II. New York: Hafner Publishing.
54. Krovat E.M., Langer T. (2003) Non-peptide angiotensin II receptor antagonists: chemical feature based pharmacophore identification. J Med Chem;46:716-726.
55. Tropsha A., Gramatica P., Gombar V. (2003) The importance of being earnest: validation is the absolute essential for successful application and interpretation of QSPR models. QSAR Comb Sci;22:69-77.
56. Kirchmair J., Markt P., Distinto S., Wolber G., Langer T. (2008) Evaluation of the performance of 3D virtual screening protocols: RMSD comparisons, enrichment assessments, and decoy selection-what can we learn from earlier mistakes? J Comput Aided Mol Des;22:213-228.
57. Verdonk M.L., Marcel L., Berdini V., Hartshorn M.J., Mooij W.T.M., Murray C.W., Taylor R.D., Watson P. (2004) Virtual screening using protein ligand docking: avoiding artificial enrichment. J Chem Inf Comput Sci;44:793-806.
58. Irwin J.J., Shoichet B.K. (2005) ZINC - a free database of commercially available compounds for virtual screening. J Chem Inf Comput Sci;45:177-182.
59. Triballeau N., Acher F., Brabet I., Pin J.-P., Bertrand H.-O. (2005) Virtual screening workflow development guided by the "Receiver Operating Characteristic" curve approach. Application to high-throughput docking on metabotropic glutamate receptor subtype 4. J Med Chem;48:2534-2547.
60. Jacobsson M., Liden P., Stjernschantz E., Bostroem H., Norinder U. (2003) Improving structure-based virtual screening by multivariate analysis of scoring data. J Med Chem;46:5781-5789.
61. Gao H., Williams C., Labute P., Bajorath J. (1999) Binary quantitative structure-activity relationship (QSAR) analysis of estrogen receptor ligands. J Chem Inf Comput Sci;39:164-168.
62. Lipinski C., Lombardo F., Dominy B., Feeney P. (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev;46:3-26.
63. Veber D., Johnson S., Cheng H., Smith B., Ward K., Kopple K. (2002) Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem;45:2615-2623.
64. National Committee for Clinical Laboratory Standards (1993) Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. Approved Standard M7-A3. Villanova, PA: National Committee for Clinical Laboratory Standards.
65. Sheridan R., Kearsley S. (2002) Why do we need so many chemical similarity search methods? Drug Discov Today;7:903-911.
66. Li H., Sutter J., Hoffmann R. (2000) In: Güner O.F., editor. Pharmacophore Perception, Development, and Use in Drug Design. California: International University Line; p. 173-189.
67. Ramsey L., Schafer W. (1997) The Statistical Sleuth, 1st edn. USA: Wadesworth Publishing Company.
68. Clement O.O., Mehl A.T. (2000) In: Güner O.F., editor. Pharmacophore Perception, Development, and Use in Drug Design. California: International University Line; p. 71-84.
69. Ostrov D.A., Law B.K., Corsino P. (2007) Cyclin-dependent kinase inhibitors, methods for their identification, and their use for the treatment of proliferative disorders. PCT Int Appl WO;2007050673:172.
70. Archer S., Zayed A.H., Rej R., Rugino T.A. (1983) Analogs of hycanthone and lucanthone as antitumor agents. J Med Chem;26:1240-1246.
71. Brown S., Sandhu G.S. (1997) Lyophilized thioxanthenone antitumor agents. PCT Int Appl WO;9710809:60.
72. Venkatachalam C.M., Jiang X., Oldfield T., Waldman M. (2003) LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites. J Mol Graphics Models;21:289-307.
73. Gehlhaar D.K., Verkhivker G.M., Rejto P.A., Sherman C.J., Fogel D.B., Fogel L.J., Freer S.T. (1995) Molecular recognition of the inhibitor AG-1343 by HIV-1 protease: conformationally flexible docking by evolutionary programming. Chem Biol;2:317-324.